Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent
07:00am, Monday, 30'th Aug 2021
DALLAS, Aug. 30, 2021 /PRNewswire/ -- Highlander Partners ("Highlander") today announced that it has entered into a definitive agreement under which Catalent, Inc. (NYSE: CTLT) will acquire Highlande
Preview: Catalent's Earnings
05:17pm, Friday, 27'th Aug 2021
CTLT is set to give its latest quarterly earnings report on Monday , 2021-08-30. Here's what investors need to know before the announcement.
Catalent Stock Hits Record High, Eyes Five-Straight Ahead of Earnings
03:23pm, Wednesday, 25'th Aug 2021
Catalent, Inc. (NYSE:CTLT) is an American company that operates in the pharmaceutical industry.
Catalent (CTLT) Earnings Expected to Grow: Should You Buy?
04:04pm, Monday, 23'rd Aug 2021
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
11:26am, Monday, 16'th Aug 2021
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
01:50pm, Monday, 26'th Jul 2021
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
08:26am, Thursday, 22'nd Jul 2021
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant
02:14pm, Wednesday, 21'st Jul 2021
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities. The plant is
Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product
11:35am, Thursday, 15'th Jul 2021
Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
09:01am, Friday, 02'nd Jul 2021
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
This Therapeutics Company Is Eyeing Zero Competition for the Next 5 Years
06:15am, Wednesday, 30'th Jun 2021
If production setbacks can be avoided, gains should be in sight.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
12:09pm, Tuesday, 29'th Jun 2021
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
12:02pm, Monday, 28'th Jun 2021
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
Catalent, Inc. to Present at the Biopharma CEO Investor Forum
09:00am, Friday, 04'th Jun 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gen
